Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

bpi labs llc - phenobarbital sodium (unii: sw9m9bb5k3) (phenobarbital - unii:yqe403bp4d) - - sedative. sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. however, thyrotoxic individuals occasionally react poorly to barbiturates. - hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see clinical pharmacology ). -  preanesthetic. - long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the t

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

bpi labs, llc - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - epinephrine injection usp, 1 mg/ml is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. none risk summary prolonged experience with epinephrine use in pregnant women over several decades, based on published literature, does not identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. however, there are risks to the mother and fetus associated with epinephrine use during labor or delivery (see clinical considerations ). in animal reproduction studies, epinephrine administered by the subcutaneous route to pregnant rabbits, mice, and hamsters, during the period of organogenesis, resulted in adverse developmental effects (including gastroschisis, embryonic lethality, and delayed skeletal ossification) at doses approximately 2 times the maximum recommended daily intramuscular, subcutaneous, or intravenous dose (see data ). the estimated background risk of major birth defects and miscarriage

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

bpi labs llc - mycophenolate mofetil hydrochloride (unii: uxh81s8zvb) (mycophenolic acid - unii:hu9dx48n0t) - mycophenolate mofetil [mycophenolate mofetil (mmf)] is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see clinical studies (14.1)], heart [see clinical studies (14.2)] or liver transplants [see clinical studies (14.3)] , in combination with other immunosuppressants. allergic reactions to mycophenolate mofetil have been observed; therefore, mycophenolate mofetil is contraindicated in patients with a hypersensitivity to mycophenolate mofetil (mmf), mycophenolic acid (mpa) or any component of the drug product. mycophenolate mofetil for injection is contraindicated in patients who are allergic to polysorbate 80 (tween). pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to mycophenolate during pregnancy and those becoming pregnant within 6 weeks of discontinuing mycophenolate mofetil treatment. to report a pregnancy or obtain inform

Australija - engleski - Department of Health (Therapeutic Goods Administration)

teleflex medical australia pty ltd - 36257 - catheter, central venous, peripherally inserted - a peripherally inserted central venous catheter (picc) manufactured with medical grade, flexible polyurethane. the arrow picc has a non-tapered catheter body with either a blunt tip or a blue flextip? that is softer than a cut tip with a contour design to enhance maneuverability. the blue flextip? also provides visual confirmation of an intact catheter upon removal. the kit components assist the clinician in maintianing maximal sterile barrier precautions. the pressure injectable picc is indicated for short or long term peripheral access to the central venous system for intravenous therapy, blood sampling, infusion, power injection of contrast media and allows for central venous pressure monitoring. the maximum pressure of power injector equipment used with the pressure injectable picc may not exceed 300 psi.

Malezija - engleski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

naturally plus malaysia sdn. bhd. - cyanocobalamin; fish oil; lutein; lycopene; riboflavin; pyridoxine hci; vitamin e; wheat germ oil (triticum vulgare); thiamine hcl; beta carotene -

Malezija - engleski - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

naturally plus malaysia sdn. bhd. - riboflavin; cyanocobalamin; pyridoxine hydrochloride; vitamin e (d-alpha tocopherol); pine bark extract (pinus pinaster); blackcurrant fruit extract (ribes nigrum); tagetes erecta (marigold) extract; elaeis guineensis (palm) oil extract; fish oil; thiamine hydrochloride; vaccinium myrtillus fruit extract (bilberry); lycopersicon esculentum (tomato) -

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

rally labs llc - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) -

Australija - engleski - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - olanzapine, quantity: 20 mg - tablet, orally disintegrating - excipient ingredients: lactose monohydrate; hyprolose; crospovidone; mannitol; magnesium stearate; aspartame; flavour - ? olanzapine is indicated for the treatment of schizophrenia and related psychoses. ? olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ? olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - olanzapine, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: lactose monohydrate; hyprolose; crospovidone; mannitol; magnesium stearate; aspartame; flavour - ? olanzapine is indicated for the treatment of schizophrenia and related psychoses. ? olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ? olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - olanzapine, quantity: 10 mg - tablet, orally disintegrating - excipient ingredients: lactose monohydrate; hyprolose; crospovidone; mannitol; magnesium stearate; aspartame; flavour - ? olanzapine is indicated for the treatment of schizophrenia and related psychoses. ? olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ? olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.